Biomerica Valuation
| BMRA Stock | USD 0.32 0.02 5.88% |
Biomerica seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Biomerica from analyzing the firm fundamentals such as Profit Margin of (1.12) %, return on equity of -0.76, and Current Valuation of 3.34 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biomerica's valuation include:
Price Book 1.0204 | Enterprise Value 3.3 M | Enterprise Value Ebitda (5.42) | Price Sales 0.9902 | Enterprise Value Revenue 0.6067 |
Undervalued
Today
Please note that Biomerica's price fluctuation is very risky at this time. Calculation of the real value of Biomerica is based on 3 months time horizon. Increasing Biomerica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biomerica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biomerica Stock. However, Biomerica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.32 | Real 3.48 | Target 13.0 | Hype 0.29 | Naive 0.28 |
The real value of Biomerica Stock, also known as its intrinsic value, is the underlying worth of Biomerica Company, which is reflected in its stock price. It is based on Biomerica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biomerica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biomerica helps investors to forecast how Biomerica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biomerica more accurately as focusing exclusively on Biomerica's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biomerica's intrinsic value based on its ongoing forecasts of Biomerica's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biomerica's closest peers. If more than one evaluation category is relevant for Biomerica we suggest using both methods to arrive at a better estimate.
Biomerica Cash |
|
Biomerica Valuation Trend
Comparing Biomerica's enterprise value against its market capitalization is a good way to estimate the value of Biomerica uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Biomerica Total Value Analysis
Biomerica is currently projected to have valuation of 3.34 M with market capitalization of 5.46 M, debt of 785 K, and cash on hands of 6.08 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biomerica fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.34 M | 5.46 M | 785 K | 6.08 M |
Biomerica Investor Information
About 13.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biomerica recorded a loss per share of 0.37. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 14th of November 1994. Based on the key measurements obtained from Biomerica's financial statements, Biomerica may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Biomerica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biomerica has an asset utilization ratio of 58.52 percent. This suggests that the Company is making $0.59 for each dollar of assets. An increasing asset utilization means that Biomerica is more efficient with each dollar of assets it utilizes for everyday operations.Biomerica Ownership Allocation
Biomerica holds a total of 16.82 Million outstanding shares. Biomerica shows 7.22 percent of its outstanding shares held by insiders and 13.01 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biomerica Profitability Analysis
The company reported the previous year's revenue of 5.42 M. Net Loss for the year was (5.98 M) with profit before overhead, payroll, taxes, and interest of 446 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biomerica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biomerica and how it compares across the competition.
About Biomerica Valuation
The stock valuation mechanism determines Biomerica's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biomerica. We calculate exposure to Biomerica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biomerica's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 611 K | 580.5 K | |
| Pretax Profit Margin | (1.10) | (1.04) | |
| Operating Profit Margin | (1.18) | (1.12) | |
| Net Loss | (1.10) | (1.05) | |
| Gross Profit Margin | 0.11 | 0.11 |
Biomerica Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.8 M |
Biomerica Current Valuation Indicators
Valuation refers to the process of determining the present value of Biomerica and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biomerica we look at many different elements of the entity such as Biomerica's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biomerica, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biomerica's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biomerica's worth.Complementary Tools for Biomerica Stock analysis
When running Biomerica's price analysis, check to measure Biomerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerica is operating at the current time. Most of Biomerica's value examination focuses on studying past and present price action to predict the probability of Biomerica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerica's price. Additionally, you may evaluate how the addition of Biomerica to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |